Thursday, August 28, 2025
News Health
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
HealthNews
No Result
View All Result
Home Health News

Can Tumor Patterns Predict Lymphoma Treatment Success?

June 19, 2025
in Health News
Share on FacebookShare on Twitter


TOPLINE:

Large B-cell lymphomas (LBCL) exhibit three distinct microenvironment archetype profiles defined by specific immune and stromal cell patterns. These profiles show divergent cell-cell communication pathways and correlate with different clinical outcomes following CD19 chimeric antigen receptor (CAR) T-cell therapy.

METHODOLOGY:

  • Researchers employed single-nucleus multiome sequencing of 232 LBCL tumors and controls to comprehensively define the cellular landscape and stereotypical patterns in lymphoma microenvironment archetype profiles.
  • Analysis included 217 lymphomas (110 newly diagnosed and 107 relapsed/refractory cases) and 15 control biopsies.
  • Control tissues comprised nonmalignant reactive lymph nodes biopsied due to suspicion of lymphoma in patients with (n = 13) or without (n = 2) prior lymphoma diagnosis.
  • Available remaining nuclei underwent DNA and RNA extraction followed by whole-exome sequencing (n = 174), low-pass whole-genome sequencing (n = 174), and bulk RNA sequencing (n = 208).

TAKEAWAY:

  • Cell subsets co-occurred in three distinct lymphoma microenvironment archetype profiles characterized by: sparsity of T cells with high frequencies of cancer-associated fibroblasts and tumor-associated macrophages; lymph node architectural cell types with naive and memory T cells; or activated macrophages and exhausted CD8+ T cells.
  • Researchers identified that divergent patterns of cell-cell communication underpinned the transcriptional phenotypes of archetype-defining cell subsets.
  • The Fibroblast/Macrophage archetype showed association with inferior outcomes following first-line rituximab plus chemotherapy treatment.
  • Analysis revealed that patients with T-cell exhausted archetype tumors had significantly higher rates of progressive disease as best response to CD19 CAR T-cell therapy (4/6) compared to Lymph Node archetype (0/8; Fisher test, P = .017).

IN PRACTICE:

“The assembly of nonmalignant components of human tumors into prototypical microenvironmental patterns, or archetypes, has been described across cancers. Each archetype consists of a dominant, interconnected cellular network that promotes tumor growth through divergent mechanisms. Furthermore, differences in cell frequency and function between microenvironment archetypes have been suggested as potential biomarkers for immunotherapy response,” the authors of the study wrote.

SOURCE:

The study was led by Michael Green, PhD, MD Anderson Cancer Center in Houston. It was published online in Cancer Cell.

LIMITATIONS:

According to the authors, the patient cohort’s clinical heterogeneity, while reflecting real-world population, limited their ability to directly assess associations between archetypes and outcomes. The researchers noted that the Fibroblast/Macrophage archetype is linked to high-risk features and increases in prevalence in later therapy lines, while the Lymph Node archetype is associated with low-risk features and declines in prevalence, potentially skewing distribution among treated patients. The authors acknowledged uncertainty about whether LymphoMAPs remain stable between diagnosis and relapse or change with treatment. The researchers emphasized the need for studying LymphoMAP archetypes in uniformly treated cohorts and randomized trials, preferably with biopsies at both baseline and relapse.

DISCLOSURES:

The study received funding from the Schweitzer family, the MD Anderson Lymphoid Malignancies Program and NCI P01 CA272295. Michael Green, PhD, reported ties with Sanofi, Kite/Gilead, Abbvie, Allogene, Bristol Myers Squibb, Arvinas, Johnson & Johnson, Daiichi Sankyo, and DAVA Oncology and stock ownership in KDAc Therapeutics. Todd Fehniger, MD, PhD, disclosed being an inventor on patent applications held by Washington University, as well as having relationships with Wugen Inc, Orca Bio, Indapta Therapeutics, HCW Biologics Inc, Affimed, AI Proteins, and the National Institutes of Health. Additional disclosures are noted in the original article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.



Source link : https://www.medscape.com/viewarticle/can-tumor-patterns-predict-lymphoma-treatment-success-2025a1000gc0?src=rss

Author :

Publish date : 2025-06-19 07:15:00

Copyright for syndicated content belongs to the linked Source.

Previous Post

What to Know About the New COVID Variant

Next Post

How to sleep in the heat

Related Posts

Health News

Cognitive Benefit From Ginkgo biloba Monotherapy in MCI

August 28, 2025
Health News

Keeping Up on Hidradenitis Suppurativa Management

August 28, 2025
Health News

How a Robot Performed Surgery Without Human Assistance

August 28, 2025
Health News

The Promise — and Price — of Needle-Free Epinephrine

August 28, 2025
Health News

Bile Acid Levels Predict Pregnancy Cholestasis Recurrence

August 28, 2025
Health News

Flood of High-Level CDC Departures Follow Director’s Exit

August 28, 2025
Load More

Keeping Up on Hidradenitis Suppurativa Management

August 28, 2025

How a Robot Performed Surgery Without Human Assistance

August 28, 2025

The Promise — and Price — of Needle-Free Epinephrine

August 28, 2025

Bile Acid Levels Predict Pregnancy Cholestasis Recurrence

August 28, 2025

Flood of High-Level CDC Departures Follow Director’s Exit

August 28, 2025

Diversity in Med School Acceptances Dips Following Ruling

August 27, 2025

CDC Director Ousted After Just Weeks, Reports Say

August 27, 2025

Medical Schools, Residency Programs Need to Add More Nutrition Education, HHS Says

August 27, 2025
Load More

Categories

Archives

August 2025
MTWTFSS
 123
45678910
11121314151617
18192021222324
25262728293031
« Jul    

© 2022 NewsHealth.

No Result
View All Result
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health

© 2022 NewsHealth.

Go to mobile version